Focus on Haemostasis

Stago's 2024 CSR report is online

The Stago Group is strengthening its commitment to Corporate Social Responsibility (CSR) and publishing its first 2024 report.

Infection COVID-19 et troubles de l’hémostase

COVID-19 infection and thrombotic disorders

Since December 2019, COVID-19 is spreading worldwide and affecting people every day.

Main symptoms are fever and cough, and most of patients recover spontaneously.

However, about 1 in 6 patients can develop breathing difficulties and in some of them the disease progresses to a more systemic disease and multiple organ dysfunction (1). Patient’s risk stratification is key to optimize COVID-19 patients flow at hospital. Stratification is currently based on characteristics of severe pneumonia and on laboratory findings.

The newest additions to Stago’s Max Generation are intelligently designed to meet the needs of today’s laboratories.

Setting the standard with exclusive mechanical technology built into all Stago systems for more than 30 years, Stago’s Viscosity-Based Detection System consistently delivers the right result, the first time.

Covid 19 impact on Stago’s range

As part of our commitment to healthcare, Stago has been closely monitoring the development of Covid 19 worldwide, implementing several actions in the past few weeks.

Evaluation des impacts médico-économiques du test Stago pour le dosage des D-dimères

Health Economics Outcomes evaluation of Stago D-dimer

Improved patient outcomes and experience, shorter length of stay and cost effectiveness drive the recognition of value in today’s rapidly-evolving and competitive healthcare environment.